Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2013

  1. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

2009

  1. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

    European Journal of Health Economics, Vol. 10, Núm. 3, pp. 255-265

2008

  1. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study

    Schizophrenia Research, Vol. 104, Núm. 1-3, pp. 1-12

  2. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

    Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 23-28

  3. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease

    Mayo Clinic Proceedings, Vol. 83, Núm. 8, pp. 870-879

2007

  1. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

    Schizophrenia Research, Vol. 90, Núm. 1-3, pp. 162-173

2006

  1. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating To New Targets (TNT) study

    Diabetes Care, Vol. 29, Núm. 6, pp. 1220-1226

  2. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

    Lancet, Vol. 368, Núm. 9539, pp. 919-928